These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

187 related items for PubMed ID: 3140797

  • 1. The iron chelators desferrioxamine and 1-alkyl-2-methyl-3-hydroxypyrid-4-ones inhibit vascular prostacyclin synthesis in vitro.
    Jeremy JY, Kontoghiorghes GJ, Hoffbrand AV, Dandona P.
    Biochem J; 1988 Aug 15; 254(1):239-44. PubMed ID: 3140797
    [Abstract] [Full Text] [Related]

  • 2. Iron chelators inhibit human platelet aggregation, thromboxane A2 synthesis and lipoxygenase activity.
    Barradas MA, Jeremy JY, Kontoghiorghes GJ, Mikhailidis DP, Hoffbrand AV, Dandona P.
    FEBS Lett; 1989 Mar 13; 245(1-2):105-9. PubMed ID: 2494068
    [Abstract] [Full Text] [Related]

  • 3. Antioxidant and free radical scavenging activities of the iron chelators pyoverdin and hydroxypyrid-4-ones in iron-loaded hepatocyte cultures: comparison of their mechanism of protection with that of desferrioxamine.
    Morel I, Cillard J, Lescoat G, Sergent O, Pasdeloup N, Ocaktan AZ, Abdallah MA, Brissot P, Cillard P.
    Free Radic Biol Med; 1992 Nov 13; 13(5):499-508. PubMed ID: 1334028
    [Abstract] [Full Text] [Related]

  • 4. Effect of novel 1-alkyl-3-hydroxy-2-methylpyrid-4-one chelators on uptake and release of iron from macrophages.
    Brock JH, Licéaga J, Arthur HM, Kontoghiorghes GJ.
    Am J Hematol; 1990 May 13; 34(1):21-5. PubMed ID: 2327400
    [Abstract] [Full Text] [Related]

  • 5. Chelation of aluminium by combining DFO and L1 in rats.
    Blanusa M, Prester L, Varnai VM, Pavlović D, Kostial K, Jones MM, Singh PK.
    Toxicology; 2000 Jul 05; 147(3):151-6. PubMed ID: 10924797
    [Abstract] [Full Text] [Related]

  • 6. Iron chelation studies using desferrioxamine and the potential oral chelator, 1,2-dimethyl-3-hydroxypyrid-4-one, in normal and iron loaded rats.
    Kontoghiorghes GJ, Sheppard L, Hoffbrand AV, Charalambous J, Tikerpae J, Pippard MJ.
    J Clin Pathol; 1987 Apr 05; 40(4):404-8. PubMed ID: 3584483
    [Abstract] [Full Text] [Related]

  • 7. Comparative efficacy and toxicity of desferrioxamine, deferiprone and other iron and aluminium chelating drugs.
    Kontoghiorghes GJ.
    Toxicol Lett; 1995 Oct 05; 80(1-3):1-18. PubMed ID: 7482575
    [Abstract] [Full Text] [Related]

  • 8. Effects on Mycobacterium avium replication in normal human macrophages by deferiprone (L1) and other iron chelators. Possible implications on toxicity.
    Douvas GS, May MH, Kolnagou A, Kontoghiorghes GJ.
    Arzneimittelforschung; 2002 Oct 05; 52(1):45-52. PubMed ID: 11838274
    [Abstract] [Full Text] [Related]

  • 9. Competition between deferiprone, desferrioxamine and other chelators for iron and the effect of other metals.
    Sheppard LN, Kontoghiorghes GJ.
    Arzneimittelforschung; 1993 Jun 05; 43(6):659-63. PubMed ID: 8352819
    [Abstract] [Full Text] [Related]

  • 10. Iron chelators induce apoptosis in proliferating cells.
    Hileti D, Panayiotidis P, Hoffbrand AV.
    Br J Haematol; 1995 Jan 05; 89(1):181-7. PubMed ID: 7833261
    [Abstract] [Full Text] [Related]

  • 11. Multidentate pyridinones inhibit the metabolism of nontransferrin-bound iron by hepatocytes and hepatoma cells.
    Chua AC, Ingram HA, Raymond KN, Baker E.
    Eur J Biochem; 2003 Apr 05; 270(8):1689-98. PubMed ID: 12694182
    [Abstract] [Full Text] [Related]

  • 12. Effect of desferrioxamine and deferiprone (L1) on the proliferation of MG-63 bone cells and on phosphatase alkaline activity.
    Naves Díaz ML, Elorriaga R, Canteros A, Cannata Andía JB.
    Nephrol Dial Transplant; 1998 Apr 05; 13 Suppl 3():23-8. PubMed ID: 9568816
    [Abstract] [Full Text] [Related]

  • 13. Cardioprotective effect of alpha-tocopherol, ascorbate, deferoxamine, and deferiprone: mitochondrial function in cultured, iron-loaded heart cells.
    Link G, Konijn AM, Hershko C.
    J Lab Clin Med; 1999 Feb 05; 133(2):179-88. PubMed ID: 9989770
    [Abstract] [Full Text] [Related]

  • 14. Comparative study of the protective effect between deferoxamine and deferiprone on chronic iron overload induced cardiotoxicity in rats.
    Emara AM, El Kelany RS, Moustafa KA.
    Hum Exp Toxicol; 2006 Jul 05; 25(7):375-85. PubMed ID: 16898166
    [Abstract] [Full Text] [Related]

  • 15. Ability of the orally effective iron chelators dimethyl- and diethyl-hydroxypyrid-4-one and of deferoxamine to restore sarcolemmal thiolic enzyme activity in iron-loaded heart cells.
    Link G, Pinson A, Hershko C.
    Blood; 1994 May 01; 83(9):2692-7. PubMed ID: 8167347
    [Abstract] [Full Text] [Related]

  • 16. Inhibition by hydrocortisone of prostacyclin synthesis by rat aorta and its reversal with RU486.
    Jeremy JY, Dandona P.
    Endocrinology; 1986 Aug 01; 119(2):661-5. PubMed ID: 3089761
    [Abstract] [Full Text] [Related]

  • 17. Angiotensin converting enzyme inhibitors (captopril, CGS14831 and CGS14824A) antagonise in vitro smooth muscle prostanoid synthesis: evidence for calcium channel blockade.
    Jeremy JY, Mikhailidis DP, Dandona P.
    Agents Actions; 1988 Jul 01; 24(3-4):381-6. PubMed ID: 3140614
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Orally active alpha-ketohydroxypyridine iron chelators: studies in mice.
    Kontoghiorghes GJ.
    Mol Pharmacol; 1986 Dec 01; 30(6):670-3. PubMed ID: 3785144
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.